Advertisement
Advertisement
ANAB
AnaptysBio, Inc. Common Stock
65.65
USDSponsored
+0.26
+0.39%
Mar 26, 13:44 UTC -4
Open
ANAB Earnings Reports
Positive Surprise Ratio
ANAB beat 23 of 37 last estimates.
62%
Next Report
Date of Next Report
May 04, 2026
Estimate for Q1 26 (Revenue/ EPS)
$28.74M
/-$1.00
Implied change from Q4 25 (Revenue/ EPS)
-73.45%
/-163.29%
Implied change from Q1 25 (Revenue/ EPS)
+3.48%
/-21.88%
AnaptysBio, Inc. Common Stock earnings per share and revenue
On Mar 03, 2026, ANAB reported earnings of 1.58 USD per share (EPS) for Q4 25, beating the estimate of 0.95 USD, resulting in a 65.05% surprise. Revenue reached 108.25 million, compared to an expected 93.89 million, with a 15.29% difference. The market reacted with a -0.25% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 10 analysts forecast an EPS of -1.00 USD, with revenue projected to reach 28.74 million USD, implying an decrease of -163.29% EPS, and decrease of -73.45% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
FAQ
What were AnaptysBio, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, AnaptysBio, Inc. Common Stock reported EPS of $1.58, beating estimates by 65.05%, and revenue of $108.25M, 15.29% above expectations.
How did the market react to AnaptysBio, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -0.25%, changed from $55.05 before the earnings release to $54.91 the day after.
When is AnaptysBio, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 04, 2026.
What are the forecasts for AnaptysBio, Inc. Common Stock's next earnings report?
Based on 10
analysts, AnaptysBio, Inc. Common Stock is expected to report EPS of -$1.00 and revenue of $28.74M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement